Gusto Global
Gusto Global is a microbiome ecology company that leverages bacteria as biosensors for early disease detection and develops advanced microbiome therapeutics. Their proprietary technology uses artificial intelligence and bacterial intelligence to analyze microbial cell-free DNA (mcfDNA) signatures in blood, enabling faster and more accurate detection of diseases like cancer. They also engineer bacteria to create the most advanced microbiome therapeutics, aiming to meaningfully and beneficially alter the human microbiome to improve patient outcomes. Gusto Global collaborates with leading physicians and patient groups, including the Crohn's and Colitis Foundation, to validate their Tapestry™ fragment sequencing platform. Their research highlights the critical role of the microbiome in various health conditions and their innovative approach to understanding and manipulating these microbial communities.
Gusto Global
Gusto Global is a microbiome ecology company that leverages bacteria as biosensors for early disease detection and develops advanced microbiome therapeutics. Their proprietary technology uses artificial intelligence and bacterial intelligence to analyze microbial cell-free DNA (mcfDNA) signatures in blood, enabling faster and more accurate detection of diseases like cancer. They also engineer bacteria to create the most advanced microbiome therapeutics, aiming to meaningfully and beneficially alter the human microbiome to improve patient outcomes. Gusto Global collaborates with leading physicians and patient groups, including the Crohn's and Colitis Foundation, to validate their Tapestry™ fragment sequencing platform. Their research highlights the critical role of the microbiome in various health conditions and their innovative approach to understanding and manipulating these microbial communities.